Display options
Cite
Barkin RL, Chor PN, Braun BG, et al. A Trilogy Case Review Highlighting the Clinical and Pharmacologic Applications of Mirtazapine in Reducing Polypharmacy for Anxiety, Agitation, Insomnia, Depression, and Sexual Dysfunction. Prim Care Companion J Clin Psychiatry. 1999;1(5):142-145doi: 10.4088/pcc.v01n0502.
Barkin, R. L., Chor, P. N., Braun, B. G., & Schwer, W. A. (1999). A Trilogy Case Review Highlighting the Clinical and Pharmacologic Applications of Mirtazapine in Reducing Polypharmacy for Anxiety, Agitation, Insomnia, Depression, and Sexual Dysfunction. Primary care companion to the Journal of clinical psychiatry, 1(5), 142-145. https://doi.org/10.4088/pcc.v01n0502
Barkin, Robert L., et al. "A Trilogy Case Review Highlighting the Clinical and Pharmacologic Applications of Mirtazapine in Reducing Polypharmacy for Anxiety, Agitation, Insomnia, Depression, and Sexual Dysfunction." Primary care companion to the Journal of clinical psychiatry vol. 1,5 (1999): 142-145. doi: https://doi.org/10.4088/pcc.v01n0502
Barkin RL, Chor PN, Braun BG, Schwer WA. A Trilogy Case Review Highlighting the Clinical and Pharmacologic Applications of Mirtazapine in Reducing Polypharmacy for Anxiety, Agitation, Insomnia, Depression, and Sexual Dysfunction. Prim Care Companion J Clin Psychiatry. 1999 Oct;1(5):142-145. doi: 10.4088/pcc.v01n0502. PMID: 15014675; PMCID: PMC181080.
Copy Download .nbib Format: NLM
Share it on

Prim Care Companion J Clin Psychiatry. 1999 Oct;1(5):142-145. doi: 10.4088/pcc.v01n0502.

A Trilogy Case Review Highlighting the Clinical and Pharmacologic Applications of Mirtazapine in Reducing Polypharmacy for Anxiety, Agitation, Insomnia, Depression, and Sexual Dysfunction.

Primary care companion to the Journal of clinical psychiatry

Robert L. Barkin, Philip N. Chor, Bennett G. Braun, William A. Schwer

Affiliations

  1. Departments of Anesthesiology, Family Medicine, Pharmacology, and Psychiatry, Rush-Presbyterian-St. Luke's Medical Center and Rush Medical College, Chicago, Ill. Dr. Braun is in private practice in Skokie, Ill.

PMID: 15014675 PMCID: PMC181080 DOI: 10.4088/pcc.v01n0502

Abstract

BACKGROUND: Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), is characterized by a unique receptor-specific pharmacologic profile and tolerable side-effect profile in comparison to other antidepressants. It has been reported to have a low incidence of agitation, anxiety, and insomnia, which may be due to blockade of 5-HT(2) and 5-HT(3) receptors. This unique multireceptor-mediated clinical pharmacologic profile may reduce the need for polypharmacy in selected patients. CASE REPORTS: Three cases are presented. In case 1, mirtazapine was able to rapidly treat anxiety and agitation in a 90-year-old woman. This was confirmed with 3 consecutive challenges with mirtazapine. In case 2, both a mood disorder and insomnia were successfully treated with rapid resolution in a patient by using mirtazapine. In case 3, the patient experienced sexual dysfunction while receiving sertraline and developed insomnia with the addition of bupropion. The addition of mirtazapine and the discontinuation of sertraline and bupropion resolved the sexual dysfunction and insomnia. Polypharmacy interventions were decreased in these patients through receptor-specific events from mirtazapine. CONCLUSION: The new antidepressant mirtazapine appears to be an effective strategy for treating anxiety, agitation, and insomnia and for diminishing SSRI-related sexual dysfunction without compromising the patient's therapeutic response to the medication while decreasing the need for additional pharmacotherapies. More than 70% of patients with major depression will have anxiety symptoms. The 5-HT(2) receptor seems to play a major role in the regulation of anxiety. The anxiolytic properties of mirtazapine may be due to its antagonism of 5-HT(2) receptors and can appear as early as the first week of treatment.

References

  1. J Clin Psychiatry. 1993 Feb;54(2):71 - PubMed
  2. Am Fam Physician. 1999 Sep 15;60(4):1101 - PubMed
  3. J Clin Psychiatry. 1983 Aug;44(8 Pt 2):8-11 - PubMed
  4. Biol Psychiatry. 2000 Jul 1;48(1):75-8 - PubMed
  5. Pharmacopsychiatry. 1996 Mar;29(2):81 - PubMed
  6. Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:37-45 - PubMed
  7. N Engl J Med. 1993 May 13;328(19):1398-405 - PubMed
  8. J Clin Psychiatry. 1996;57 Suppl 4:19-25 - PubMed
  9. J Clin Psychiatry. 1998 Mar;59(3):123-7 - PubMed
  10. J Clin Psychiatry. 1999 Apr;60(4):260-1 - PubMed
  11. Am J Health Syst Pharm. 1998 Oct 15;55(20):2195-6 - PubMed
  12. Psychopharmacology (Berl). 1992;108(3):248-55 - PubMed
  13. Acta Psychiatr Scand Suppl. 1997;391:31-7 - PubMed
  14. Arch Gen Psychiatry. 1992 Jul;49(7):580-1 - PubMed
  15. Pharmacotherapy. 1997 Jan-Feb;17(1):10-21 - PubMed
  16. J Clin Psychiatry. 1997;58 Suppl 8:35-40 - PubMed
  17. J Clin Psychiatry. 1994 Feb;55 Suppl:34-44 - PubMed
  18. J Clin Psychiatry. 1998 Jun;59(6):306-12 - PubMed
  19. J Clin Psychiatry. 1988 Mar;49(3):100-4 - PubMed
  20. J Clin Psychiatry. 1997;58 Suppl 8:11-6 - PubMed
  21. J Affect Disord. 1998 Dec;51(3):267-85 - PubMed

Publication Types